A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
A phase 2 trial of Pembrolizumab in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT06978114 by Sichuan Baili Pharmaceutical Co., Ltd., with 46 participants planned, started 2025-06-10 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1 and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Shares SystImmune / Sichuan Biokin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Shares SystImmune / Sichuan Biokin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.